VivoSeq
Cardiovascular

Cardiovascular Risk Factor

0

Pipeline Programs↗

3

Active Trials↗

4

Companies Involved↗

Cardiovascular Risk Factor is an early-stage landscape with 0 programs across 4 companies. The most active players are Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Pronova BioPharma, Sanofi.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

81/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

0 programs

PreclinicalP

Pronova BioPharma

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalBayer logo

Bayer

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

20

clinical trials

Completed13 · 65%
Terminated3 · 15%
Recruiting2 · 10%
Active, not recruiting1 · 5%
Unknown status1 · 5%

Clinical Trials

Trial Activity

20 trials

Effect of Metyrapone on Cardiovascular Risk Factors in Patients With Adrenal Incidentalomas and Cushing's Syndrome
Recruiting·IIRCCS Azienda Ospedaliero-Universitaria di Bologna·Phase 4·NCT06801249·50 enrolled
Evaluation of Cardiovascular Risk Factors in Incident Dialysis Patients
Recruiting·UUniversity Hospital, Montpellier·N/A·NCT02813642·400 enrolled
"Community-based, eHealth Supported Management of Cardiovascular Risk Factors by Lay Village Health Workers (ComBaCaL aHT TwiC 1 & ComBaCaL aHT TwiC 2)
Active, not recruiting·UUniversity Hospital, Basel, Switzerland·N/A·NCT05684055·1,354 enrolled
The Effect of Vitamin D Supplementation on Cardiovascular Risk Factors
Completed·UUniversity of Tromso·Phase 3·NCT02750293·411 enrolled
Omega-3 Fatty Acids to Improve Depression and Reduce Cardiovascular Risk Factors
Completed·WWashington University School of Medicine·Phase 3·NCT00116857·122 enrolled
Ramadan Fasting Effects in Patients With Cardiovascular Risk Factors
Completed·UUniversity of Monastir·N/A·NCT02720133·500 enrolled
Omacor and Cardiovascular Risk Factors in HIV Patients on HAART Treatment
Completed·PPronova BioPharma·Phase 4·NCT00296153·51 enrolled
GH and Cardiovascular Risk Factors
Completed·AAmsterdam UMC, location VUmc·Phase 4·NCT01877512·32 enrolled
Effects of Doxazosin Gastrointestinal Therapeutic System on Ambulatory Blood Pressure and Cardiovascular Risk Factors in Uncontrolled Hypertensive Patients
Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00646841·89 enrolled
ACE Inhibition and Novel Cardiovascular Risk Factors
Completed·National Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00051389
Omega 3 Action on Cardiovascular Risk Factors in Patients Treated With Statins
Completed·—·N/A·NCT00976872·52 enrolled
Vitamin D Supplementation on Cardiovascular Risk Factors
Completed·FFlorida International University·N/A·NCT01412710·92 enrolled
Association Between the Prevalence of Cardiovascular Risk Factors and New Use of Testosterone
Completed·Bayer logoBayer·N/A·NCT03484260·27,778 enrolled
Consumption of Oral Artificial Sweeteners on Platelet Aggregation and Polyol Excretion
Completed·TThe Cleveland Clinic·Preclinical·NCT04731363·50 enrolled
Effects of Choline From Eggs vs. Supplements on the Generation of TMAO in Humans (EGGS)
Completed·TThe Cleveland Clinic·Preclinical·NCT03039023·86 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)